Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 189

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Cohort Study of Somatostatin-Based Radiopeptide Therapy With [90Y-DOTA]-TOC Versus [90Y-DOTA]-TOC Plus [177Lu-DOTA]-TOC in Neuroendocrine Cancers

Open access
Villard, Linda, Romer, Anna, Marincek, Nicolas, Brunner, Philippe, Koller, Michael T., Schindler, Christian, Ng, Quinn K.T., Mäcke, Helmut R., Müller-Brand, Jan, Rochlitz, Christoph, Briel, Matthias, Walter, Martin A. · 2012 · Journal of Clinical Oncology

Abstract

Purpose: Radiopeptide therapy is commonly performed with a single radioisotope. We aimed to compare the effectiveness of somatostatin-based radiopeptide therapy with a single versus a combination of radioisotopes. Patients and Methods: In a cohort study, patients with metastasized neuroendocrine cancer were treated with repeated cycles of 90 yttrium-labeled tetraazacyclododecane-tetraacetic acid modified Tyr-octreotide ([90 Y-DOTA]-TOC) or with cycles alternating between [90 Y-DOTA]-TOC and 177 lutetium-labeled DOTA-TOC ([177 Lu-DOTA]-TOC) until tumor progression or permanent toxicity. Multivariable Cox regression and competing risk regression were used to study predictors of survival and renal toxicity in patients completing three or more treatment cycles. Results: A total of 486 patients completed three or more treatment cycles; 237 patients received [90 Y-DOTA]-TOC and 249 patients received [90 Y-DOTA]-TOC + [177 Lu-DOTA]-TOC. Patients receiving [90 Y-DOTA]-TOC + [177 Lu-DOTA]-TOC had a significantly longer survival than patients receiving [90 Y-DOTA]-TOC alone (5.51 v 3.96 years; hazard ratio, 0.64; 95% CI, 0.47 to 0.88; P = .006). The rates of severe hematologic toxicities (6.3% v 4.4%; P = .25) and severe renal toxicity (8.9% v 11.2%; P = .47) were comparable in both groups. Conclusion: [90 Y-DOTA]-TOC + [177 Lu-DOTA]-TOC was associated with improved overall survival compared with [90 Y-DOTA]-TOC alone in patients completing three or more cycles of treatment. Contrary to the current practice in radiopeptide therapy, our results suggest an advantage of using a combination of radioisotopes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2011.37.2151

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 189

Metadata

Authors
Villard, L., Romer, A., Marincek, N., Brunner, P., Koller, M. T., Schindler, C., Ng, Q. K. T., Mäcke, H. R., Müller-Brand, J., Rochlitz, C., Briel, M., & Walter, M. A.
Venue
Journal of Clinical Oncology
Published
2012-04-01
Volume
30
Issue
10
Pages
1100-1106
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2148881212
Cited by
189
References
2
FWCI
14.86
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cohort Study of Somatostatin-Based Radiopeptide Therapy With [90Y-DOTA]-TOC Versus [90Y-DOTA]-TOC Plus [177Lu-DOTA]-TOC in Neuroendocrine Cancers. https://app.cochat.ai/papers/10.1200/jco.2011.37.2151
The paper
Villard, L., Romer, A., Marincek, N., Brunner, P., Koller, M. T., Schindler, C., Ng, Q. K. T., Mäcke, H. R., Müller-Brand, J., Rochlitz, C., Briel, M., & Walter, M. A. (2012). Cohort Study of Somatostatin-Based Radiopeptide Therapy With [90Y-DOTA]-TOC Versus [90Y-DOTA]-TOC Plus [177Lu-DOTA]-TOC in Neuroendocrine Cancers. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2011.37.2151

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.